Cargando…

Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis

Fecal microbiota transplantation (FMT) has been recognized as a promising treatment for dysbiosis-related diseases. Since 2014, FMT has been utilized to treat ulcerative colitis (UC) in our clinical studies and has shown efficacy and safety. As donor screening (DS) is the primary step to ensure the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaochen, Ishikawa, Dai, Nomura, Kei, Fukuda, Naoyuki, Haraikawa, Mayuko, Haga, Keiichi, Shibuya, Tomoyoshi, Mita, Toshihiro, Nagahara, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879222/
https://www.ncbi.nlm.nih.gov/pubmed/35207328
http://dx.doi.org/10.3390/jcm11041055
_version_ 1784658847436111872
author Zhang, Xiaochen
Ishikawa, Dai
Nomura, Kei
Fukuda, Naoyuki
Haraikawa, Mayuko
Haga, Keiichi
Shibuya, Tomoyoshi
Mita, Toshihiro
Nagahara, Akihito
author_facet Zhang, Xiaochen
Ishikawa, Dai
Nomura, Kei
Fukuda, Naoyuki
Haraikawa, Mayuko
Haga, Keiichi
Shibuya, Tomoyoshi
Mita, Toshihiro
Nagahara, Akihito
author_sort Zhang, Xiaochen
collection PubMed
description Fecal microbiota transplantation (FMT) has been recognized as a promising treatment for dysbiosis-related diseases. Since 2014, FMT has been utilized to treat ulcerative colitis (UC) in our clinical studies and has shown efficacy and safety. As donor screening (DS) is the primary step to ensure the safety of FMT, we report our experience with DS and present the screening results to improve the prospective DS criteria and provide references for future studies. The donor candidates were screened according to the DS criteria. The first DS criteria were proposed in June 2014 and revised substantially in May 2018. We further sorted the screening results and costs of laboratory tests. From June 2014 to April 2018, the DS eligibility rate was 50%. The total laboratory testing cost for each candidate was JPY 17,580/USD 160.21. From May 2018 to September 2021, the DS eligibility rate was 25.6%. The total laboratory testing cost for each candidate was JPY 40,740/USD 371.36. The reduction in donor eligibility rates due to more stringent criteria should be considered for cost and safety. Studies must consider the latest updates and make timely modifications in the DS criteria to ensure patient safety.
format Online
Article
Text
id pubmed-8879222
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88792222022-02-26 Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis Zhang, Xiaochen Ishikawa, Dai Nomura, Kei Fukuda, Naoyuki Haraikawa, Mayuko Haga, Keiichi Shibuya, Tomoyoshi Mita, Toshihiro Nagahara, Akihito J Clin Med Article Fecal microbiota transplantation (FMT) has been recognized as a promising treatment for dysbiosis-related diseases. Since 2014, FMT has been utilized to treat ulcerative colitis (UC) in our clinical studies and has shown efficacy and safety. As donor screening (DS) is the primary step to ensure the safety of FMT, we report our experience with DS and present the screening results to improve the prospective DS criteria and provide references for future studies. The donor candidates were screened according to the DS criteria. The first DS criteria were proposed in June 2014 and revised substantially in May 2018. We further sorted the screening results and costs of laboratory tests. From June 2014 to April 2018, the DS eligibility rate was 50%. The total laboratory testing cost for each candidate was JPY 17,580/USD 160.21. From May 2018 to September 2021, the DS eligibility rate was 25.6%. The total laboratory testing cost for each candidate was JPY 40,740/USD 371.36. The reduction in donor eligibility rates due to more stringent criteria should be considered for cost and safety. Studies must consider the latest updates and make timely modifications in the DS criteria to ensure patient safety. MDPI 2022-02-17 /pmc/articles/PMC8879222/ /pubmed/35207328 http://dx.doi.org/10.3390/jcm11041055 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Xiaochen
Ishikawa, Dai
Nomura, Kei
Fukuda, Naoyuki
Haraikawa, Mayuko
Haga, Keiichi
Shibuya, Tomoyoshi
Mita, Toshihiro
Nagahara, Akihito
Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
title Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
title_full Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
title_fullStr Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
title_full_unstemmed Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
title_short Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
title_sort donor screening revisions of fecal microbiota transplantation in patients with ulcerative colitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879222/
https://www.ncbi.nlm.nih.gov/pubmed/35207328
http://dx.doi.org/10.3390/jcm11041055
work_keys_str_mv AT zhangxiaochen donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT ishikawadai donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT nomurakei donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT fukudanaoyuki donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT haraikawamayuko donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT hagakeiichi donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT shibuyatomoyoshi donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT mitatoshihiro donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis
AT nagaharaakihito donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis